Stock listing

Lang & Schwarz:A2P208 Oric Pharmaceuticals, Inc. Aktie

German listing (Lang & Schwarz) of Oric Pharmaceuticals, Inc. · home listing NASDAQ:ORIC

Follow Oric Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ORIC

$12.35 USD -0.42 (-3.3%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ORIC

Ticker: Lang & Schwarz:A2P208
Asset type: Stock
Sector: Health care
Industry: Biotechnology
Exchange: Lang & Schwarz
Currency: EUR

What changed lately

Latest news release · Oct 5, 2026
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 49 slides

Calls

Replays

Oric Pharmaceuticals (NASDAQ:ORIC) Q4 2021 Earnings Call
Mon, Mar 21, 2022 · 5:00 PM ET
Watch Transcript

Latest news

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

Oct 5, 2026

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2026

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

Aug 3, 2026

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Jul 20, 2026

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

Jul 14, 2026

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

May 4, 2026

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Apr 17, 2026

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

Mar 31, 2026

ORIC Pharmaceuticals to Report Combination Dose Optimization Data from Phase 1b Trial of Rinzimetostat in Patients with mCRPC

Mar 30, 2026

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Mar 17, 2026

All Oric Pharmaceuticals, Inc. news

Decks

Investor Presentation (September 2026)
Investor deck · 49 slides · September 2026
Corporate Update (March 2026)
Corporate update · 44 slides · Mar 31, 2026
Technical Presentation (December 2025)
Technical · 43 slides · Dec 8, 2025
Technical Presentation (December 2025)
Technical · 19 slides · Dec 6, 2025

Oric Pharmaceuticals, Inc. on 6ix

Sector: Health care
Industry: Biotechnology
News releases: 26 in the last 12 months · 131 in all · newest Oct 5, 2026 · oldest 2020
Calls: 1 call with a replay · 1 with a transcript · latest Mar 21, 2022
Decks: 10 decks · latest September 2026

Where Oric Pharmaceuticals, Inc. is listed

Listing	Exchange	Country	Currency
NASDAQ:ORIC · Home listing	NASDAQ	United States	USD
LS Exchange:A2P208	LS Exchange	Germany	EUR
Lang & Schwarz:A2P208 · This page	Lang & Schwarz	Germany	EUR
gettex:4TZ	gettex	Germany	EUR
BOATS:ORIC	BOATS	United States	USD
Tradegate:4TZ	Tradegate	Germany	EUR
Dusseldorf:4TZ	Dusseldorf	Germany	EUR
Frankfurt:4TZ	Frankfurt	Germany	EUR
Hamburg:4TZ	Hamburg	Germany	EUR
Munich:4TZ	Munich	Germany	EUR
Stuttgart:4TZ	Stuttgart	Germany	EUR

Log in to ask 6ix AI your own questions about Oric Pharmaceuticals, Inc.